Targeting glycans for CAR therapy: The advent of sweet CARs

Area of Science:

• Oncology
• Immunology
• Biochemistry

Background:

• Chimeric antigen receptor (CAR) T cell therapy has revolutionized hematologic malignancy treatment.
• CAR T cell efficacy against solid tumors is limited by scarce tumor-specific antigens and a hostile tumor microenvironment.
• Cancer cells exhibit profound dysregulation in glycosylation, the post-translational addition of sugars to proteins or lipids.

Purpose of the Study:

• To review the current status of CAR T cell therapy in solid tumors.
• To explore the cancer glycoproteome as a potential therapeutic target.
• To discuss the potential and future of glycan-binding CAR T cell therapy.

Main Methods:

• Review of existing literature on CAR T cell therapy for solid tumors.
• Analysis of the cancer glycoproteome and its relevance to CAR T cell targeting.
• Discussion of glycan-binding CAR T cell strategies.

Main Results:

• Abnormally glycosylated glycoproteins on cancer cells present unique, tumor-specific targets for CAR T therapy.
• Tumor stromal cells also express abnormal glycoproteins, making them potential targets for glycan-binding CAR T cells.
• CAR T cell therapy faces significant challenges in solid tumors, including antigen scarcity and the tumor microenvironment.

Conclusions:

• Glycan-binding CAR T cell therapy offers a promising strategy to overcome current limitations in solid tumor treatment.
• Targeting the cancer glycoproteome represents a novel therapeutic avenue.
• Further research into glycan-binding CAR T cells is warranted to improve solid tumor therapy outcomes.